コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 oms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 x 10(10) viral particles or MenACWY as a singl
2 n lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks,
3 thrombosis or pulmonary embolism to receive oral apixaban (at a dose of 10 mg twice daily for the first 7 days, followed
4 aily for the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose o
5 receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (riva
6 loroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days.
7 r aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg daily for the first 3 months) (antiplatele
9 or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once d
10 exiform neurofibromas received oral selumetinib twice daily at a dose of 25 mg per square meter of body-surface area on a
11 , followed by 5 mg twice daily) or subcutaneous dalteparin (at a dose of 200 IU per kilogram of body weight once daily fo
12 gned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive
13 evere pruritus to receive either intravenous difelikefalin (at a dose of 0.5 mug per kilogram of body weight) or placebo
14 ts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days
15 and UF-2]) to evaluate the efficacy and safety of elagolix at a dose of 300 mg twice daily with hormonal "add-back" ther
16 astatic ROS1 fusion-positive NSCLC who received entrectinib at a dose of at least 600 mg orally once per day, with at lea
17 randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily.
18 tween the groups assigned to receive intravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram and the
19 tients) or placebo (41 patients); or intravenous evinacumab at a dose of 15 mg per kilogram of body weight every 4 weeks
20 y assigned to the following groups: subcutaneous evinacumab at a dose of 450 mg weekly (40 patients), 300 mg weekly (43 p
21 ween the groups assigned to receive subcutaneous evinacumab at a dose of 450 mg weekly, 300 mg weekly, and 300 mg every 2
22 g therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks
23 than two antiretroviral classes to add either fostemsavir (at a dose of 600 mg twice daily) or placebo to their failing
24 Adjunctive hydrocortisone therapy (hydrocortisone at a dose of 200 mg/d for 7 d for Adjunctive Corticosteroid T
25 00 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose o
26 eceive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydrox
27 ng technique that provides high-quality and accurate images at a dose of 148 MBq (4.0 mCi) for the detection of somatosta
28 Erythropoietin was administered intravenously at a dose of 1000 U per kilogram of body weight every 48 hour
29 gular red-cell transfusions to receive either luspatercept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) o
30 lassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or
32 ulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients m
33 se of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m(2) (maximum of 100 mg) twice daily.
34 ek, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered
35 assigned the infants in a 2:1 ratio to receive nirsevimab, at a dose of 50 mg in a single intramuscular injection, or pl
38 sion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule.
39 inoma in situ (DCIS) were randomly assigned to radiotherapy at a dose of either 50 Gy in 25 fr or 40 Gy in 15 fr.
40 successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of
41 nticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100
42 ad undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated w
43 r 12 to 16 weeks, after which they received IONIS-PKK-L(Rx) at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months.
44 ia to receive subcutaneous injections of inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270,
45 roup A (n = 24), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in patients who had pre
46 roup B (n = 18), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in patients who were an
47 went MRI of the chest and abdomen with ferumoxytol at 3.0 T at a dose of 4 mg per kilogram of body weight.
48 ged ocular drug retention and did not cause ocular toxicity at a dose of 150 mug of active agent.
49 e a single intravenous injection of recombinant factor VIII at a dose of 25 IU per kilogram of body weight (lower-dose gr
50 70 QRM was 60% (range, 48%-72%) and was significantly worse at a dose of 5 QRM and lower, whether or not IR was used (P <
51 conditioning chemotherapy and a single infusion of KTE-X19 at a dose of 2x10(6) CAR T cells per kilogram of body weight.